C. diff Risk


Oral Bioavailability


Spectrum Of Activity


500 mg PO BID

30+ mL/min0 - 30 mL/min500 mg PO BID500 mg PO daily

500 mg PO daily - give dose after dialysis on dialysis days

500 mg PO BID

500 mg PO daily

General Information

Additional Information

Very high tissue penetration and concentration intracellularly means in vivo activity may not be predicted by in vitro testing.

May exacerbate muscle weakness in persons with myasthenia gravis. Avoid Use.

Adverse Effects

  • Neutropenia

  •  GI upset

  •  Prolongation of QTc interval

  •  Drug interactions

Drug Monitoring

Monitor QTc in patients with increased risk

Major Interactions

  •  CYP450 interactions ++

  •  Other QTc prolonging agents

  •  Recommend review of pt medications due to high frequency of significant interactions

  •  Statins - increased rhabdo

  •  CCBs - hypotension, AKI

  • Colchicine - increased bone marrow toxicity

  •  Increased tacrolimus levels

  •  Increased phenytoin levels

  • Increased INR with warfarin


Antimicrobial class: Macrolide

Pregnancy category: C